Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays.

[1]  M. Fenning,et al.  The synthesis and radiolabelling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. , 1997 .

[2]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[3]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[4]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[5]  L. Coia,et al.  Prediction of tumour hypoxia and radioresistance with nuclear medicine markers. , 1996, The British journal of cancer. Supplement.

[6]  M. Parliament,et al.  Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. , 1996, The British journal of cancer. Supplement.

[7]  A. Rauth,et al.  In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  R. Hill,et al.  Comparing techniques of measuring tumor hypoxia in different murine tumors: Eppendorf pO2 Histograph, [3H]misonidazole binding and paired survival assay. , 1996, Radiation research.

[9]  C. Koch,et al.  2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. , 1996, Cancer research.

[10]  G. Adams,et al.  Bioreductive drugs for cancer therapy: the search for tumor specificity. , 1994, International journal of radiation oncology, biology, physics.

[11]  T L Phillips,et al.  Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. , 1993, Radiation research.

[12]  C. Grau,et al.  Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[15]  J. D. Chapman,et al.  Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[17]  J. Rasey,et al.  Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. , 1990, Radiation research.

[18]  K. Krohn,et al.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.

[19]  J. Lee,et al.  Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. , 1989, International journal of radiation oncology, biology, physics.

[20]  C. J. Koch,et al.  A novel technique for measuring human tissue pO2 at the cellular level. , 1986, British Journal of Cancer.

[21]  C. Coleman,et al.  Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. , 1986, International journal of radiation oncology, biology, physics.

[22]  D. Hirst,et al.  Changes in misonidazole binding with hypoxic fraction in mouse tumors. , 1985, International journal of radiation oncology, biology, physics.

[23]  J. Chapman,et al.  The detection and measurement of hypoxic cells in solid tumors , 1984, Cancer.

[24]  B. Garrecht,et al.  The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. , 1983, The British journal of radiology.

[25]  J. D. Chapman,et al.  Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. , 1983, Cancer research.

[26]  S. Dische,et al.  Clinical experience with nitroimidazoles as radiosensitizers. , 1982, International journal of radiation oncology, biology, physics.

[27]  J. D. Chapman,et al.  A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.

[28]  Chapman Jd,et al.  Hypoxic sensitizers--implications for radiation therapy. , 1979 .

[29]  G. Whitmore,et al.  Studies on the toxicity and radiosensitizing ability of misonidazole under conditions of prolonged incubation. , 1978, Radiation research.

[30]  A. J. Varghese,et al.  Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. , 1976, Cancer research.

[31]  P. Band,et al.  Radiation and high-dose metronidazole in supratentorial glioblastomas. , 1976, The New England journal of medicine.

[32]  L. V. van Putten,et al.  Oxygenation status of a transplantable tumor during fractionated radiation therapy. , 1968, Journal of the National Cancer Institute.

[33]  I. Silver,et al.  Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapy. , 1960, Acta radiologica.

[34]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[35]  N. A. Powell,et al.  Radiopharmaceuticals for Imaging Hypoxia , 1996 .

[36]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[38]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[40]  P Vaupel,et al.  Blood flow and tissue oxygenation of human tumors: an update. , 1992, Advances in experimental medicine and biology.

[41]  P. Workman.  Keynote address: Bioreductive mechanisms☆ , 1992 .

[42]  J. Chapman.  Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  J. Lee,et al.  Adduct Formation by 2-Nitroimidazole Drugs in Mammalian Cells: Optimization of Markers for Tissue Oxygenation , 1990 .

[44]  R. McCLELLAND.  Molecular Interactions and Biological Effects of the Products of Reduction of Nitroimidazoles , 1990 .

[45]  E. Glatstein,et al.  Seduced by oxygen. , 1988, International journal of radiation oncology, biology, physics.

[46]  J. Chapman.  The cellular basis of radiotherapeutic response , 1984 .

[47]  C. Stobbe,et al.  Radiation-Induced and Metabolism-Induced Reactions of Hypoxic Sensitizers with Cellular Molecules , 1982 .

[48]  Duane F. Bruley,et al.  Oxygen transport to tissue , 1973 .

[49]  P Kolstad,et al.  Intercapillary distance, oxygen tension and local recurrence in cervix cancer. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.